Tillotts Pharma specialises in one area of therapy, diseases of the lower gastrointestinal tract.
The products that Tillotts is responsible for treat two disease conditions:

* inflammatory bowel disease (IBD)
* irritable bowel syndrome (IBS)

SALES & MARKETING
Tillotts markets two brands:

* Asacol®, which through the efforts of licensees and distributors has become the leading product worldwide for the treatment of Inflammatory Bowel Disease (IBD), consisting of Crohn's disease and ulcerative colitis, and
*
Colpermin®, a naturally based remedy for the treatment of symptoms of Irritable Bowel Syndrome (IBS).

5-ASA
Asacol
Colpermin
Crohn's disease
Epanova
IBD
IBS
Inflammatory bowel disease
Irritable bowel syndrome
Mesalazine
Peppermint oil
Tillotts
Ulcerative Colitis
Topasa

Tillotts is a small, fast growing pharmaceutical company based near Basel, in Switzerland.

Asacol, Colpermin, Epanova, Topasa and Xenema are Trade Marks or registered Trade Marks of Tillotts Pharma AG.   23.02.2010   Tillotts Pharma in-licenses novel technology   Tillotts Pharma in-licenses novel technology from the School of Pharmacy, University of ...        02.01.2010   New Tillotts' Headquarter in Rheinfelden, Switzerland   Find below details of our new headquarters' address – from 4th of January 2010 – along with our other office locations.  ...        25.09.2009   Zeria - Tillotts Closing of Acqusition    ...        26.09.2007   Tillotts Pharma AG & the School of Pharmacy,University of London   Tillotts Pharma AG announces research collaboration with the School of Pharmacy, University of London to develop a next generation of Asacol®  ...        02.05.2007   Termination of EPIC Phase III Clinical Trial   Termination of EPIC Phase III Clinical Trial  ...        08.02.2007   Development & Marketing of Asacol in Japan   Tillotts Parma announces agreement for joint development and marketing of Asacol in Japan, between Zeria Pharmaceutical and Kyowa Hakko Kogyo  ...        02.02.2004   Tillotts Pharma licenses rights for Asacol in Japan   Tillotts Pharma AG and Zeria Pharmaceutical Company Limited announced today the signing of a Licensing Agreement for the exclusive development, ...        01.03.2003   Tillotts Pharma AG licenses Asacol® in 11 countries to Lek Pharmaceuticals   Tillotts Pharma AG announces the signing of an agreement with Lek Pharmaceuticals d.d., for the marketing & distribution rights to Asacol® in 11 ...        23.01.2003   Tillotts Pharma AG license out the rights of Asacol® in Korea   Tillotts Pharma AG announces today, that it has signed an agreeagreement with Daewoong Pharmaceutical for the distribution & marketing rights of ...        13.01.2003   Tillotts re-acquires the German rights for Asacolitin®   Tillotts Pharma AG announces today, that it has acquired the stock, the distribution & marketing rights and the brand name Asacolitin from its ...

© 2007 by tillotts pharma ag – all rights reserved | designed by senger interactive    fotos: keystone science (visual center and right) | tillotts pharma ag

	quick search
	ABOUT TILLOTTS THERAPEUTIC AREAS OUR PRODUCTS FAQ's PRODUCT DEVELOPMENT BUSINESS DEVELOPMENT CONTRACT MANUFACTURE PRESS RELEASE Job Opportunities
	Home   Contact   Sitemap   Links   Legal disclaimer   Date of last update 15 January 2010